Humacyte Inc · Q3 2023 earnings

Briefing

Announced third quarter results, highlighting positive top line results from the V005 Phase 2/3 trial and progress towards planned BLA filing.

Humacyte announced positive top line results from its V005 Phase 2/3 trial of the HAV in vascular trauma repair and plans to file a BLA for an indication in vascular trauma with the FDA during the current quarter. The company reported cash and cash equivalents of $100.0 million as of September 30, 2023.

• Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair.
• BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter.
• The HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks.
• Cash and cash equivalents of $100.0 million as of September 30, 2023.

Headline financials

Revenue & EPS history

Humacyte believes that its cash and cash equivalents and expected funding from the Oberland arrangement are adequate to finance operations past the currently anticipated timelines for FDA approval and commercialization of the HAV in the vascular trauma indication.